AmbioPharm

US-based GMP peptide API manufacturer. FDA-inspected facilities. Full analytical development and validation services. Provides comprehensive batch documentation and COAs for all GMP and non-GMP peptides. Major expansion to commercial-scale production by 2027.

AmbioPharm is listed as a CDMO in the peptide supply chain, serving North America markets from USA. As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is supported by 1 independent source, including documentation review and cross-referencing against public records. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.